Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy

详细信息    查看全文

• 作者：Mariana Reza (1)
  Anders Bjartell (2)
  Mattias Ohlsson (3)
  Reza Kaboteh (4)
  Per Wollmer (1)
  Lars Edenbrandt (1) (4)
  Elin Tr盲g氓rdh (1)
  
  1. Division of Clinical Physiology and Nuclear Medicine ; Department of Clinical Sciences ; Sk氓ne University Hospital ; Malm枚 ; Lund University ; Inga Marie Nilssons gata 49 ; Malm枚 ; SE-205 02 ; Sweden
  2. Division of Urological Cancers ; Department of Clinical Sciences ; Sk氓ne University Hospital ; Malm枚 ; Lund University ; Lund ; 22100 ; Sweden
  3. Department of Astronomy and Theoretical Physics ; Lund University ; Lund ; 22100 ; Sweden
  4. Department of Molecular and Clinical Medicine ; Sahlgrenska University Hospital ; Gothenburg ; 413 45 ; Sweden
  
• 关键词：Prostate cancer ; Bone Scan Index ; Androgen deprivation therapy ; Bone metastases
• 刊名：EJNMMI Research
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：4
• 期：1
• 全文大小：842 KB
• 参考文献：1. Bastian, PJ, Boorjian, SA, Bossi, A, Briganti, A, Heidenreich, A, Freedland, SJ, Montorsi, F, Roach, M, Schr枚der, F, Poppel, H, Stief, CG, Stephenson, AJ, Zelefsky, MJ (2012) High-risk prostate cancer: from definition to contemporary management. Eur Urol 61: pp. 1096-1106 CrossRef
  2. N酶rgaard, M, Jensen, A脴, Jacobsen, JB, Cetin, K, Fryzek, JP, S酶rensen, HT (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urology 184: pp. 162-167 CrossRef
  3. Rigaud, J, Tiguert, R, Normand, L, Karam, G, Glemain, P, Buzelin, JM, Bouchot, O (2002) Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol 168: pp. 1423-1426 CrossRef
  4. Thoreson, GR, Gayed, BA, Chung, PH, Raj, GV (2014) Emerging therapies in castration-resistant prostate cancer. Can J Urol 21: pp. 98-105
  5. Briganti, A, Passoni, N, Ferrari, M, Capitanio, U, Suardi, N, Gallina, A, Pozzo, LF, Picchio, M, Girolamo, V, Salonia, A, Gianolli, L, Messa, C, Rigatti, P, Montorsi, F (2010) When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 57: pp. 551-558 CrossRef
  6. Heidenreich, A, Bastian, PJ, Bellmunt, J, Bolla, M, Joniau, S, Kwast, T, Mason, M, Matveev, V, Wiegel, T, Zattoni, F, Mottet, N (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent鈥攗pdate 2013. Eur Urol 65: pp. 124-137 CrossRef
  7. Imbriaco, M, Larson, SM, Yeung, HW, Mawlawi, OR, Erdi, Y, Venkatraman, ES, Scher, HI (1998) A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res 4: pp. 1765-1772
  8. Dennis, ER, Jia, X, Mezheritskiy, IS, Stephenson, RD, Schoder, H, Fox, JJ, Heller, G, Scher, HI, Larson, AM, Morris, MJ (2012) Bone Scan Index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol 30: pp. 519-524 CrossRef
  9. Ulmert, D, Kaboteh, R, Fox, JJ, Savage, C, Evans, MJ, Lilja, H, Abrahamsson, PA, Bj枚rk, T, Gerdtsson, A, Bjartell, A, Gjertsson, P, H枚glund, P, Lomsky, M, Ohlsson, M, Richter, J, Sadik, M, Morris, MJ, Scher, HI, Sj枚strand, K, Yu, A, Suurk眉la, M, Edenbrandt, L, Larson, SM (2012) A novel automated platform for quantifying the extent of skeletal tumor involvement in prostate cancer patients using Bone Scan Index. Eur Urol 62: pp. 78-84 CrossRef
  10. Kaboteh, R, Damber, JE, Gjertsson, P, H枚glund, P, Lomsky, M, Ohlsson, M, Edenbrandt, L (2013) Bone Scan Index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy. EJNMMI Res 3: pp. 9 CrossRef
  11. Ulmert, D, O'Brien, MF, Bjartell, AS, Lilja, H (2009) Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol 6: pp. 384-391 CrossRef
  12. Haibe-Kains, B, Desmedt, C, Sotiriou, C, Bontempi, G (2008) A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?. Bioinformatics 24: pp. 2200-2208 CrossRef
  13. Scher, HI, Halabi, S, Tannock, I, Morris, M, Sternberg, CN, Carducci, MA, Eisenberger, MA, Higano, C, Bubley, GJ, Dreicer, R, Petrylak, D, Kantoff, P, Basch, E, Kelly, WK, Figg, WD, Small, EJ, Beer, TM, Wilding, G, Martin, A, Hussain, M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: pp. 1148-1159 CrossRef
  14. Kaboteh, R, Gjertsson, P, Leek, H, Lomsky, M, Ohlsson, M, Sj枚strand, K, Edenbrandt, L (2013) Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan index. EJNMMI Res 3: pp. 64 CrossRef
  15. Mitsui, Y, Shiina, H, Yamamoto, Y, Haramoto, M, Arichi, N, Yasumoto, H, Kitagaki, H, Igawa, M (2012) Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int 110: pp. 628-634 CrossRef
  
• 刊物主题：Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology;
• 出版者：Springer Berlin Heidelberg
• ISSN：2191-219X

文摘

Background Bone Scan Index (BSI) is a quantitative measurement of tumour burden in the skeleton calculated from bone scan images. When analysed at the time of diagnosis, it has been shown to provide prognostic information on survival in men with metastatic prostate cancer (PCa). In this study, we evaluated the prognostic value of BSI during androgen deprivation therapy (ADT). Methods Prostate cancer patients who were at high risk of a poor outcome and who had undergone bone scan at the time of diagnosis and during ADT were recruited from two university hospitals for a retrospective study. BSI at baseline and follow-up were calculated using an automated software package (EXINIbonebsi). Associations between BSI, other prognostic biomarkers and overall survival (OS) were evaluated using a Cox proportional hazards regression model. Results One hundred forty-six PCa patients were included in the study. A total of 102 patient deaths were registered, with a median survival time after the follow-up bone scan of 2.4 years (interquartile range (IQR) =0.8 to 4.4). Both at baseline and during ADT, BSI was significantly associated with OS in univariate and multivariate analyses. When BSI was added to a prognostic base model including age, prostate-specific antigen, clinical tumour stage and Gleason score, the concordance index increased from 0.73 to 0.77 (p =0.0005) at baseline and from 0.77 to 0.82 (p Conclusions Automated BSI during ADT is an independent prognostic indicator of OS in PCa patients with bone metastasis. It represents an emerging imaging biomarker that can be used in a prognostic model for risk stratification of PCa patients at the time of diagnosis and at later stages of the disease. BSI could then help physicians identify patients who could benefit from more aggressive therapies.